Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a hypomethylating agent has recently become standard of care front-line therapy for patients who are unfit for high intensity induction chemotherapy and allogeneic stem cell transplantation. However, for patients who experience disease refractoriness/relapse, second line treatment options are limited. Natural killer (NK) cells have been shown to have potent anti-tumor effects in AML may represent a potential therapeutic option for patients with progression after venetoclax-based therapy.